Macquarie Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Macquarie Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,697	Closed	-$40K	–	2478
2020 Q4	$40K	Hold	11,697	–	–	﹤0.01%	2092
2020 Q3	$17K	Hold	11,697	–	–	﹤0.01%	2198
2020 Q2	$23K	Hold	11,697	–	–	﹤0.01%	2133
2020 Q1	$23K	Hold	11,697	–	–	﹤0.01%	1906
2019 Q4	$49K	Sell	11,697 -438,303	-97%	-$1.69M	﹤0.01%	1852
2019 Q3	$1.35M	Hold	450,000	–	–	﹤0.01%	1134
2019 Q2	$2.83M	Hold	450,000	–	–	﹤0.01%	924
2019 Q1	$2.5M	Buy	+450,000	New	+$2.73M	﹤0.01%	941
2017 Q3	–	Sell	-104,566	Closed	-$1.72M	–	2145
2017 Q2	$1.72M	Buy	104,566 +36,300	+53%	+$562K	﹤0.01%	1013
2017 Q1	$979K	Sell	68,266 -165	-0.2%	-$2.45K	﹤0.01%	1186
2016 Q4	$946K	Buy	68,431 +12,531	+22%	+$201K	﹤0.01%	1171
2016 Q3	$1.01M	Buy	+55,900	New	+$900K	﹤0.01%	1146

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's LXRX Position: Q1 2021 in Review

Macquarie Group sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 11,697 shares — an estimated $40K sold.

Macquarie Group first reported a position in LXRX in Q3 2016 and held it in 12 quarters. The position peaked at $2.83M in Q2 2019. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

Macquarie Group reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Macquarie Group sold 11,697 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $40K.
Macquarie Group first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 12 quarters.
Macquarie Group's Lexicon Pharmaceuticals position peaked at $2.83M in Q2 2019.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Macquarie Group's 13F filing for Q1 2021, filed 14 May 2021.